Results 191 to 200 of about 112,312 (307)

Diabetic Infantilism with Diabetic Nephropathy [PDF]

Proceedings of the Royal Society of Medicine, 1952
openaire   +2 more sources

Glucagon‐Like Peptide‐1 Receptor Agonists and Incident Major Adverse Liver Outcomes in People With Type 2 Diabetes and Metabolic Dysfunction‐Associated Steatotic Liver Disease

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Treatment options for metabolic dysfunction‐associated steatotic liver disease (MASLD) are limited. While glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA) and sodium‐glucose cotransporter‐2 (SGLT‐2) inhibitors improve cardiovascular outcomes, comparative effectiveness on liver‐related outcomes remains unclear.
Gregor A. Maier, Ramon A. Hofmann, Michael Roden, Wolfgang Rathmann, Oliver Kuss   +4 more
wiley   +1 more source

Association between serum lipid levels and the risk of diabetic nephropathy: a meta-analysis. [PDF]

Front Endocrinol (Lausanne)
Cai L, Li X, Yang Q, Liu F.
europepmc   +1 more source

Risk of Severe Hypoglycemia Associated With Concomitant Use of Sulfonylureas and Amiodarone

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To evaluate whether initiation of amiodarone while receiving sulfonylurea is associated with an increased risk of severe hypoglycemia compared with the initiation of other antiarrhythmic agents (flecainide, sotalol, or propafenone) while receiving sulfonylurea. Materials and Methods We conducted a population‐based cohort study using South
Sungho Bea, Hyesung Lee, Young Min Cho, You‐Jung Choi, Ju‐Young Shin, Katsiaryna Bykov   +5 more
wiley   +1 more source

A Novel Cross Injection Analysis for Simultaneous Multi-Determination of Diabetic Nephropathy Biomarkers in Urine. [PDF]

Molecules
Inpota P, Choengchan N.
europepmc   +1 more source

Association of Variability of Monthly Continuous Glucose Monitoring‐Derived Metrics With Diabetic Kidney Disease in Type 1 Diabetes

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background While HbA1c is the standard for monitoring long‐term glycaemic control, it fails to capture glycaemic variability. We investigated the discriminatory capacity of longitudinal continuous glucose monitoring (CGM) metrics and identified CGM metric patterns associated with diabetic kidney disease (DKD) in individuals with type 1 ...
Byeongjae Kang, Rosa Oh, Taeyoung Kim, Jee Hee Yoo, Danbee Kang, Gyuri Kim, Sang‐Man Jin, Myung Jin Chung, Jae Hyeon Kim   +8 more
wiley   +1 more source

ADAMTS13 ameliorates diabetic nephropathy by Nrf2/GPX4/eNOS signaling pathway. [PDF]

Ren Fail
Wang H, Guo J, Wang Q, Cai F, Jiang S, Fei L, Zhang G, Yu G, Li B, Zhou J, Li Z, Han F, Lai EY, Zhou S.   +13 more
europepmc   +1 more source

Effect of Medications for Type 2 Diabetes on Cardiovascular Events and Mortality: A Comprehensive Pairwise and Network Meta‐Analysis

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aim To assess the effect of all the approved classes of medications for type 2 diabetes on Major Adverse Cardiovascular events (MACE) and all‐cause mortality. Methods We performed a pairwise and network meta‐analysis, including randomised controlled trials with a duration of at least 40 weeks, comparing medications versus placebo or an active ...
Giovanni Antonio Silverii, Valerio Velardi, Christian Marinelli, Antonino Lax, Matteo Monami, Edoardo Mannucci   +5 more
wiley   +1 more source

Sodium-Glucose Cotransporter 2 Inhibitors in Diabetic Nephropathy: A Systematic Review and Meta-Analysis. [PDF]

Cureus
Rajput J, Rajput PV, Jena N, Mariswamy Arun Kumar AK, Mohanty E, Parsi S.   +5 more
europepmc   +1 more source

Impact of Albuminuria‐Lowering Treatments on Cardiovascular Predictive Ceramides in Diabetes: Post Hoc Analysis of the ROTATE Trials

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aim Cardiovascular disease (CVD) is the leading cause of mortality in individuals with diabetes. Diabetic kidney disease, closely related to CVD risk, is prevalent in up to 40% of this population. Emerging evidence suggests ceramide lipids as accurate biomarkers for CVD.
Kristina Pigsborg, Simon Maria Kienle, Asger Wretlind, Viktor Rotbain Curovic, Martin Bæk Blond, Hiddo J. L. Heerspink, Tine Willum Hansen, Frederik Persson, Karolina Sulek, Cristina Legido‐Quigley, Peter Rossing   +10 more
wiley   +1 more source